Barclays PLC Acquires 51,873 Shares of Omeros Co. (NASDAQ:OMER)

Barclays PLC lifted its position in Omeros Co. (NASDAQ:OMER - Free Report) by 121.3% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 94,640 shares of the biopharmaceutical company's stock after purchasing an additional 51,873 shares during the quarter. Barclays PLC owned about 0.16% of Omeros worth $376,000 at the end of the most recent reporting period.

A number of other hedge funds also recently made changes to their positions in OMER. Bank of New York Mellon Corp increased its stake in Omeros by 16.6% in the 2nd quarter. Bank of New York Mellon Corp now owns 218,580 shares of the biopharmaceutical company's stock worth $887,000 after acquiring an additional 31,081 shares during the last quarter. Rhumbline Advisers grew its holdings in shares of Omeros by 6.1% in the second quarter. Rhumbline Advisers now owns 111,778 shares of the biopharmaceutical company's stock valued at $454,000 after purchasing an additional 6,435 shares in the last quarter. AQR Capital Management LLC bought a new stake in Omeros in the second quarter worth $105,000. SG Americas Securities LLC bought a new stake in Omeros in the third quarter worth $80,000. Finally, SPC Financial Inc. purchased a new stake in Omeros during the third quarter valued at $77,000. 48.79% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

OMER has been the topic of a number of research reports. Needham & Company LLC restated a "hold" rating on shares of Omeros in a report on Friday. RODMAN&RENSHAW raised Omeros to a "strong-buy" rating in a research note on Thursday, November 14th. StockNews.com upgraded Omeros from a "sell" rating to a "hold" rating in a research report on Wednesday, November 20th. Rodman & Renshaw initiated coverage on Omeros in a report on Thursday, November 14th. They issued a "buy" rating and a $9.00 target price for the company. Finally, Cantor Fitzgerald restated a "neutral" rating on shares of Omeros in a report on Thursday, November 14th. Three investment analysts have rated the stock with a hold rating, two have given a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average price target of $22.50.

Omeros Price Performance

Shares of NASDAQ:OMER traded up $0.15 during trading hours on Friday, hitting $9.33. 522,245 shares of the company's stock traded hands, compared to its average volume of 1,000,426. The firm has a market capitalization of $540.67 million, a P/E ratio of -4.04 and a beta of 2.01. The business has a fifty day moving average price of $9.35 and a 200-day moving average price of $6.03. Omeros Co. has a 1 year low of $2.61 and a 1 year high of $13.60.

Omeros Profile

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company's products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19.